For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Pembrolizumab: Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) | 35 | None | 8 | 60 | 24 | 60 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| fatigue | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| pruritis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| elevated liver enzyme | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | None | View |
| hyperbilirubinemina | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | None | View |
| diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| hyperthyroidism | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |